Gene · 81607
Papers1,879
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
161 to 180 of 1,879
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Outcomes and Management of Dermatologic Toxicity Following Enfortumab Vedotin Rechallenge in Patients With Metastatic Urothelial Carcinoma: A Retrospective Single-Center Study. | Cancer Rep (Hoboken) | 2026 | 41578675 | PubTator, text mining | PubMed |
| Expression of antibody drug conjugate target antigens in ovarian sex cord stromal Tumors. | Gynecol Oncol | 2026 | 41576550 | PubTator, text mining | PubMed |
New insights into Nectin-4 expression in testicular choriocarcinoma and its potential treatment with Enfortumab Vedotin: analysis of a multi-institutional series and association with clinical-pathological features. | Virchows Arch | 2026 | 41559359 | PubTator, text mining | PubMed |
| Real-world use of enfortumab vedotin in metastatic urothelial carcinoma: efficacy, safety, and risk stratification. | Ther Adv Urol | 2026 | 41555863 | PubTator, text mining | PubMed |
| From Cloudy to Clear: A Strategy to Resolve the Complex Structural Elucidation of Bicycle Drug Conjugate Zelenectide Pevedotin by NMR. | Bioconjug Chem | 2026 | 41553133 | PubTator, text mining | PubMed |
| Early-onset fatal toxic epidermal necrolysis after first-cycle enfortumab vedotin in an elderly patient with metastatic urothelial carcinoma. | Urol Case Rep | 2026 | 41552399 | PubTator, text mining | PubMed |
| Clinicopathologic and Immunohistochemical Features of Enfortumab Vedotin-Induced Cutaneous Toxicity. | Int J Dermatol | 2026 | 41540292 | PubTator, text mining | PubMed |
| Cytotoxic and Antileishmanial Potential of Pilocarpus microphyllus Essential Oil: In Vitro and In Silico Study. | Chem Biodivers | 2026 | 41532848 | PubTator, text mining | PubMed |
| Supplementary biomarker testing in molecular tumor boards increases actionable therapy recommendations: a prospective real-world study of 658 patients. | BMC Med | 2026 | 41530754 | PubTator, text mining | PubMed |
| Identification of a Muscle-Invasive Bladder Carcinoma Molecular Subtype of Poor Responders to Neoadjuvant Chemotherapy and High Expression of Targetable Biomarkers. | Int J Mol Sci | 2026 | 41516353 | PubTator, text mining | PubMed |
| Sarcomatoid urothelial carcinoma: advances and challenges. | Curr Opin Urol | 2026 | 41505638 | PubTator, text mining | PubMed |
| Nectin-4 PET for predicting enfortumab vedotin dose-response in urothelial carcinoma. | Sci Adv | 2026 | 41499516 | PubTator, text mining | PubMed |
| Biodistribution, dosimetry, and preliminary imaging of the novel Nectin-4-targeting PET tracer [⁶⁸Ga]Ga-FZ-NR-1 in humans. | EJNMMI Res | 2026 | 41485193 | PubTator, text mining | PubMed |
| Long-Term Control after Intermittent Reintroduction of Enfortumab Vedotin in Metastatic Urothelial Carcinoma: A Case Report. | Case Rep Oncol | 2026 | 41479590 | PubTator, text mining | PubMed |
| Cavitation of Pulmonary Metastases During Enfortumab Vedotin for Metastatic Ureteral Urothelial Carcinoma. | IJU Case Rep | 2026 | 41472900 | PubTator, text mining | PubMed |
| Targeted therapies for urothelial carcinoma: From FGFR inhibitors to next‑generation antibody-drug conjugates (Review). | Int J Oncol | 2026 | 41456439 | PubTator, text mining | PubMed |
| Systematic profiling of tumor-associated antigen expression for antibody-drug conjugate in prostate cancer. | Prostate Cancer Prostatic Dis | 2026 | 41444470 | PubTator, text mining | PubMed |
| Salvage Surgery for Primary Renal Pelvic Urothelial Carcinoma After Enfortumab Vedotin: A Case of Durable Remission With Nectin-4 Loss. | IJU Case Rep | 2026 | 41403786 | PubTator, text mining | PubMed |
| Molecular pathology of bladder cancer. | Histopathology | 2026 | 41384708 | PubTator, text mining | PubMed |
| Nectin-4-Targeted Radiotheranostics for Personalized Cancer Therapy: A Systematic Review. | J Nucl Med | 2026 | 41381237 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/81607/papers?page=9